Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
telaprevir + sofosbuvir
- Development stage
- Discontinued
- Lead developer
- Vertex
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Telaprevir + sofosbuvir is a combination of two direct acting antiviral (DAA) agents used in the treatment of chronic hepatitis C virus (HCV) infection. Telaprevir is an NS3/4A serine protease inhibitor that blocks viral replication by inhibiting the cleavage of HCV polyproteins into mature proteins necessary for viral replication[2][5]. Sofosbuvir is a nucleotide analog inhibitor targeting the HCV NS5B RNA-dependent RNA polymerase, acting as a chain terminator to prevent further synthesis of viral RNA[6]. Both drugs are used as part of combination regimens for HCV, though telaprevir was withdrawn from the US market in 2014 due to safety and efficacy concerns compared to newer therapies[3]. The primary indication for both drugs is chronic hepatitis C infection.
- Other names
- none
02
Targets
NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)
Beyond the preview
Go deeper on telaprevir + sofosbuvir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on telaprevir + sofosbuvir.